Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
about
Angiogenesis inhibitors for the treatment of ovarian cancerSilencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell deathTargeted agents in epithelial ovarian cancer: review on emerging therapies and future developmentsProfile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectivesOvarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a ChallengeBeyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian CancerTargeting angiogenesis in gynecologic cancersTargeted anti-vascular therapies for ovarian cancer: current evidenceContemporary use of bevacizumab in ovarian cancerClinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancerCombination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.New perspectives on targeted therapy in ovarian cancerAngiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancerThe Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review.New developments in treatment of ovarian carcinoma: focus on trabectedinA Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.A current review of targeted therapeutics for ovarian cancer.Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic reviewRapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.Investigational agents in development for the treatment of ovarian cancerA phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.Development of second-generation VEGFR tyrosine kinase inhibitors: current status.Cediranib for metastatic alveolar soft part sarcomaThe effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.Identification of receptor tyrosine kinase, discoidin domain receptor 1 (DDR1), as a potential biomarker for serous ovarian cancer.Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.Practical considerations in ovarian cancer chemotherapy.An update on PARP inhibitors for the treatment of cancerAnti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancerTherapeutic advances in women's cancersA network model for angiogenesis in ovarian cancer.Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-SensitivSignificance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction
P2860
Q24234292-6FD327C1-FCC1-45A3-AA07-EB8850C2C137Q24632721-F0069844-E7CB-44F3-AECE-4B39E3417BECQ26750649-0F5A5088-299F-4B88-A77B-1D03F67F61D7Q26751280-D1DF8F2B-F1DE-4B8E-B51F-AF3DA54A36C5Q26777846-F1AA3A40-AC53-49C2-A61B-753BC28D0B64Q26779120-537B9665-8854-4710-9DFE-03EFE665E9FCQ26824766-E8940BA0-2974-47A6-A91D-DED24F8F1FA6Q26830287-47796004-95C8-475A-9D51-401115C411B7Q27023510-550EF15F-55B7-4A04-96B2-7EB0ADD40A57Q27024235-CF05A576-E828-4D72-A78F-95E6D242792FQ27853070-97E79ECC-CF31-458D-A669-3C2563BD2252Q28082524-E066187A-EB5C-469F-AD28-03491956D33FQ28732124-7DF5D587-0884-4B04-8474-F5FB556875E5Q30248645-B2537C5D-16A6-4B2C-B178-2E8C75625CA4Q33393429-4F286E19-0582-4526-9AC0-9E409709AD12Q33408735-B9201DC2-DC2F-4313-9926-6DF70667AD4EQ33563963-6CD6D0CF-DFDC-4D61-AA6E-4C81481FAE15Q33580998-23443BC7-1948-48CA-9705-DFF6AF38A4CCQ33662162-FDA05C1A-34CF-4A9E-BC68-9B05177E3428Q33684042-FEF4D720-9C65-481E-9E39-D8B72BDE62D8Q33920800-00E00C6A-4757-4291-B97A-6B708579D896Q34488671-4576A3B1-C5EF-49C2-B8A4-C7868C3C7823Q34514973-CF52FF9E-BB60-4E26-BF73-838ADCA9827AQ34616440-81959AC4-CFA5-43B1-92FF-1EC6C52A44A7Q34651131-55AA0001-B599-4B0C-B368-7C7B42FF814FQ34725749-BD43B7BA-A024-4F6F-9C19-2728C46AA76AQ34874796-A3473018-7C7D-45C9-8826-A8BA870CD822Q34878868-0915980E-B5D8-4C35-A4F9-BB445D9DD01EQ35076260-BD9F4F45-0D6C-4832-A30F-0111A67112E8Q35142718-547EEF98-6DCC-4B28-A318-DBEEADE289D8Q35205410-01D261D3-1424-4CAC-9EB0-54FEEDE9B884Q35233993-0E3C1135-CA90-4D03-9C54-CD1631F5A0B8Q35263056-34A53551-8292-470D-ADD5-CCEEC603B1E4Q35418973-9288B3C3-35BA-4A6B-BFE9-BEA66B85CB53Q35534413-1E127B7F-4A7F-41BF-8488-0287DBDC95A6Q35602123-F7AB5817-F2B7-4BD4-96D8-FD07A56D0AEAQ35659433-369B71DC-3942-4700-8E7E-B33C3C95A623Q35669792-0D87A033-A251-4F7A-A620-AD3DB1F8D2D5Q35954103-7B7C8DF4-426F-4ECA-848F-9CB7384754B7Q36013452-A78F9C6A-825F-4511-BC58-A79B3D2A38F3
P2860
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cediranib, an oral inhibitor o ...... n tube, and peritoneal cancer.
@en
Cediranib, an oral inhibitor o ...... n tube, and peritoneal cancer.
@nl
type
label
Cediranib, an oral inhibitor o ...... n tube, and peritoneal cancer.
@en
Cediranib, an oral inhibitor o ...... n tube, and peritoneal cancer.
@nl
prefLabel
Cediranib, an oral inhibitor o ...... n tube, and peritoneal cancer.
@en
Cediranib, an oral inhibitor o ...... n tube, and peritoneal cancer.
@nl
P2093
P2860
P356
P1476
Cediranib, an oral inhibitor o ...... n tube, and peritoneal cancer.
@en
P2093
Anna Berkenblit
Benjamin D Humphreys
Carolyn Krasner
Christin Whalen
Corrine Zarwan
Karin Tyburski
Laura Sullivan
P2860
P304
P356
10.1200/JCO.2009.23.2777
P407
P577
2009-10-13T00:00:00Z